Clinical trial

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

NCT03823378

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-05-13

PhasePHASE2

Study timeline

Study start (actual)2019-05-13Date precision: day

Registry last updated2021-09-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritis (RA)unresolved

Interventions

ElsubrutinibDRUG

UpadacitinibDRUG · verified · RxNorm: upadacitinib

Placebo for elsubrutinibDRUG

Placebo for upadacitinibDRUG

Sponsors & collaborators

AbbVielead sponsor

Mapped research locations

WinnipegManitoba, Canada2 TorontoOntario, Canada1 MadridSpain1 BarcelonaSpain1 WarsawPoland1 BudapestHungary1 ValenciaSpain1 EdmontonAlberta, Canada1 LeuvenBelgium1 SaskatoonSaskatchewan, Canada1 GranadaSpain1 OxfordUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03823378 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.